ERBB2 and non-small cell lung carcinoma: Actionable ERBB2 mutations (Exon20 insertion, G660D, V842I) were detected in 5.7% of cases (n = 3); these are predictive of response to Trastuzumab Deruxtecan, the first FDA-approved drug for HER2-mutant NSCLC.